JP2021501151A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501151A5
JP2021501151A5 JP2020523324A JP2020523324A JP2021501151A5 JP 2021501151 A5 JP2021501151 A5 JP 2021501151A5 JP 2020523324 A JP2020523324 A JP 2020523324A JP 2020523324 A JP2020523324 A JP 2020523324A JP 2021501151 A5 JP2021501151 A5 JP 2021501151A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
atopic dermatitis
composition according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020523324A
Other languages
English (en)
Japanese (ja)
Other versions
JP7218364B2 (ja
JP2021501151A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/057682 external-priority patent/WO2019084383A1/en
Publication of JP2021501151A publication Critical patent/JP2021501151A/ja
Publication of JP2021501151A5 publication Critical patent/JP2021501151A5/ja
Application granted granted Critical
Publication of JP7218364B2 publication Critical patent/JP7218364B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020523324A 2017-10-27 2018-10-26 Jakキナーゼ阻害剤としてのピリミジン化合物 Active JP7218364B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27
US62/577,852 2017-10-27
PCT/US2018/057682 WO2019084383A1 (en) 2017-10-27 2018-10-26 PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS

Publications (3)

Publication Number Publication Date
JP2021501151A JP2021501151A (ja) 2021-01-14
JP2021501151A5 true JP2021501151A5 (enExample) 2021-09-30
JP7218364B2 JP7218364B2 (ja) 2023-02-06

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523324A Active JP7218364B2 (ja) 2017-10-27 2018-10-26 Jakキナーゼ阻害剤としてのピリミジン化合物

Country Status (38)

Country Link
US (7) US10308646B2 (enExample)
EP (1) EP3672965B1 (enExample)
JP (1) JP7218364B2 (enExample)
KR (1) KR102613503B1 (enExample)
CN (1) CN111247142B (enExample)
AR (1) AR113803A1 (enExample)
AU (1) AU2018354370B2 (enExample)
BR (1) BR112020008015A2 (enExample)
CA (1) CA3074034A1 (enExample)
CL (1) CL2020001090A1 (enExample)
CR (1) CR20200180A (enExample)
CU (1) CU24671B1 (enExample)
DK (1) DK3672965T3 (enExample)
DO (1) DOP2020000083A (enExample)
EA (1) EA202091016A1 (enExample)
EC (1) ECSP20023795A (enExample)
ES (1) ES2932526T3 (enExample)
GE (2) GEAP202115340A (enExample)
HR (1) HRP20221221T1 (enExample)
HU (1) HUE060401T2 (enExample)
IL (1) IL274037B2 (enExample)
LT (1) LT3672965T (enExample)
MA (1) MA49956B1 (enExample)
MD (1) MD3672965T2 (enExample)
MX (1) MX2020004255A (enExample)
NI (1) NI202000032A (enExample)
PE (1) PE20201495A1 (enExample)
PH (1) PH12020500528A1 (enExample)
PL (1) PL3672965T3 (enExample)
PT (1) PT3672965T (enExample)
RS (1) RS63608B1 (enExample)
SG (1) SG11202001706RA (enExample)
SI (1) SI3672965T1 (enExample)
SM (1) SMT202200409T1 (enExample)
TW (1) TWI789446B (enExample)
UA (1) UA125130C2 (enExample)
WO (1) WO2019084383A1 (enExample)
ZA (1) ZA202001641B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49956B1 (fr) * 2017-10-27 2022-11-30 Theravance Biopharma R&D Ip Llc Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
CN115925705B (zh) * 2018-11-30 2024-12-31 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
JP7470713B2 (ja) * 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
JP7482152B2 (ja) * 2019-04-24 2024-05-13 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 皮膚疾患の処置のためのピリミジンjak阻害剤 発明の背景
BR112023001283A2 (pt) * 2020-07-28 2023-02-14 Arcutis Biotherapeutics Inc Composição farmacêutica tópica; método para tratar uma doença, distúrbio ou afecção inflamatória de pele em um indivíduo que necessita do mesmo; e método para intensificar a penetração em pele em um indivíduo de uma formulação farmacêutica tópica
JP2023543670A (ja) * 2020-08-26 2023-10-18 ナロ・セラピューティクス Mycファミリー癌原遺伝子タンパク質のモジュレーター
WO2022076771A1 (en) * 2020-10-08 2022-04-14 Icahn School Of Medicine At Mount Sinai Compositions for treatment alopecia areata, biomarkers for treatment success, and methods of use thereof
JP2024516299A (ja) * 2021-05-03 2024-04-12 インサイト・コーポレイション 結節性痒疹の治療のためのルキソリチニブ
TW202311256A (zh) * 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療fxr誘發之搔癢之il-31調節劑
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
EP4447930A1 (en) 2021-12-15 2024-10-23 Arcutis Biotherapeutics, Inc. Stable formulations of shr0302
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
JP2008525422A (ja) 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
ATE508126T1 (de) 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
TW200817391A (en) 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
AU2007269540B2 (en) 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
RU2014129740A (ru) 2011-12-22 2016-02-10 Ф.Хоффманн-Ля Рош Аг Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (enExample) 2014-08-21 2018-03-31
JP2017535520A (ja) * 2014-09-30 2017-11-30 ハンミ・ファイン・ケミカル・カンパニー・リミテッドHanmi Fine Chemical Co., Ltd. 高純度の(r)−9−[2−(ホスホノメトキシ)プロピル]アデニンの製造方法
ES2924698T3 (es) 2015-05-28 2022-10-10 Theravance Biopharma R&D Ip Llc Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
WO2017189822A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
MA49956B1 (fr) 2017-10-27 2022-11-30 Theravance Biopharma R&D Ip Llc Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
JP7482152B2 (ja) 2019-04-24 2024-05-13 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 皮膚疾患の処置のためのピリミジンjak阻害剤 発明の背景
JP7470713B2 (ja) 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物

Similar Documents

Publication Publication Date Title
HU225852B1 (en) Pyrazine derivatives, process for producing them, pharmaceutical compositions containing them and their use
JP2013514356A (ja) ピロロ[2,3−d]ピリミジン化合物
IL274037B2 (en) A pyrimidine compound as a JAK kinase inhibitor
AU2020299526B2 (en) Bax inhibitors and uses thereof
JPH06511251A (ja) ヒスタミンh↓3アゴニスト/アンタゴニストとしてのイミダゾリル−アルキル−ピペラジンおよび−ジアゼピン誘導体
CA2540768A1 (en) Pyrazolo and imidazo-pyrimidine derivatives
RU2010119458A (ru) 1,3,5-тризамещенное производное триазола
JP2010132669A (ja) ストロンチウムラネレートのアルファー(α)−結晶形、その製造方法、及びそれを含む医薬組成物
CN110092787A (zh) 一种化合物或其药用盐或组合物的制备及应用
JP2015516968A5 (enExample)
JP6673218B2 (ja) ジヒドロナフタレン誘導体
JP2014533264A (ja) 三環式化合物、それらを含む組成物およびそれらの使用
TW202208336A (zh) Enpp1調節劑及其用途
JP2017533237A (ja) 強力なγ−セクレターゼモジュレータ
JP2025504379A5 (enExample)
MX2025001439A (es) Dímeros de 3-etilamino-indol como agentes serotoninérgicos útiles para el tratamiento de trastornos relacionados con los mismos
CN117062819A (zh) 多环化合物及其用途
EP3458440B1 (en) Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease
EP2968331A1 (en) Pyrimidine compounds as kinase inhibitors
WO2024155846A1 (en) Compositions useful for modulating splicing
EA003941B1 (ru) 2-аминопиридины, содержащие конденсированные кольца в качестве заместителей
JP2024517789A5 (enExample)
CN121226319A (zh) 烯基取代的哌啶类化合物及其药物组合物、制备方法和用途
WO2024155836A1 (en) Compositions useful for modulating splicing
CN117586204A (zh) 异硒唑酮类化合物、其合成方法及用途